'. Box-plot presentation of the ratios of three different mAb-mAb immunofluorometric LH assays to an oligo mAb IFMA (7 capture mAbs + 10 detector mAbs).
Serum samples tested were from control subjects (n 10) and subjects with PCOD (n 50), HA (n = 8), and CAF (n = 15). P < 0.01, P < 0.001. to that antibody when tested in an excess reagent system. Well-defined and clearly stated quantitative criteria are needed when assigning a certain specificity to a mAb.
A more serious shortcoming of the previous studies by Carayon et al. (7) is the way the specificities were determined, i.e., by estimating the binding of each mAb to antigen preparations directly adsorbed onto a plastic surface. As has been reported (11), the immobilization of antigens to a plastic surface may result in deformation or preferential blocking of some of the epitopes compared with their appearance in solution.
This phenomenon is widely recognized in the development of monoelonal antibodies. Screening of antibodies by using coated antigens will frequently detect only the coated antigen and not the native conformation. The results from an epitope study with such a basic methodological flaw are inevitably a target for justifiable doubt.
A detailed dissection of the results from our and Carayon's group according to these lines may possibly resolve some of the apparent contradictions that Carayon et al. have referred to previously (6, 7) and in the present communication.
The question relating to what information is misleading may hopefully also be seen in a new, more constructive light. saline solutions of bupropion and three of its major metabolites and analyzing these solutions with the monoclonal Emit II immunoassay. The results (Table 1) indicate that all four compounds cross-react to some extent. The erythro amino alcohol metabohite appeared to cross-react the most; the threo and morpholinol metabohites and bupropion itself were less reactive. On a molar basis, the assay is quite selective: even the erythro metabolite at 417 mo1fL gave only about the same response as the 6.7 mol/L methamphetamine calibrator.
The patient's urine exhibited reac- The reactivity of the negative calibrator was set at 0 on the Hitachi 717. The calibrator containing 1 mg/L d-methamphetamine gave a reading of 48 mA/mm; urine samples with values greater than that of this calibrator are considered to be "positive" according to the manufacturer.
tivities (1 unit of reactivity being defined as 1 mAlmin at 340 nm) in the 60-65
range (see Table 1 ), significantly greater than the 48 mA/mm for the 1 mg/L methamphetamine calibrator. The combination of the high concentration of the threo metabolite and its modest cross-reactivity (Table  1) explains a large portion of the assay reactivity observed in the patient's urine. Despite its much lower concentration, the erythro metabohite may also have been a significant contributor; the morphohinol metabohite and the parent drug probably were not.
